|
業務類別
|
Biotechnology |
|
業務概覽
|
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders. |
| 公司地址
| 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 444-8400 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.enveric.com |
| 員工數量
| 6 |
| Mr. Kevin M. Coveney |
Chief Financial Officer and Principal Accounting Officer |
美元 396.55K |
14/04/2026 |
| Dr. Joseph Tucker, PhD |
Chief Executive Officer and Director |
美元 472.40K |
14/04/2026 |
| Dr. Peter Facchini, PhD |
Chief Innovation Officer |
美元 221.78K |
14/04/2026 |
|
|
| Ms. Sheila DeWitt |
Director |
14/04/2026 |
| Dr. Marcus Schabacker, M.D.,PhD |
Independent Director |
14/04/2026 |
| Dr. Joseph Tucker, PhD |
Chief Executive Officer and Director |
14/04/2026 |
| Mr. Frank Pasqualone |
Independent Director |
14/04/2026 |
| Mr. Michael D. Webb |
Chairman of the Board |
14/04/2026 |
| Mr. George Kegler |
Independent Director |
14/04/2026 |
|
|
|
|
